Original article

Association between biomass formation and the prognosis of infective endocarditis due to *Staphylococcus aureus*

Nuria Fernández-Hidalgo\(^a,b,\)\(^*\), Jana Basas\(^a,b\), Ester Viedma\(^b,c\), Aida Ribera\(^d\), Nieves Larrosa\(^b,e\), Dafne Pérez-Montarelo\(^b,c\), Fernando Chaves\(^b,c\), Joan Gavalda\(^a,b\), Benito Almirante\(^a,b\)

\(^a\) Servei de Malalties Infeccioses, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
\(^b\) Red Española de Investigación en Patología Infecciosa, Instituto de Salud Carlos III, Madrid, Spain
\(^c\) Servei de Microbiologia, Hospital Universitari 12 de Octubre, Madrid, Spain
\(^d\) Unitat d’Epidemiologia Cardiovascular, Servei de Cardiologia, Hospital Universitari Vall d’Hebron, CIBERESP, Barcelona, Spain
\(^e\) Servei de Microbiologia, Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain

**Article history:**
Received 18 July 2019
Accepted 15 October 2019

**Keywords:**
*Staphylococcus aureus*
Infective endocarditis
Biofilm
Biomass
Optical density
Prognosis

**Abstract**

**Introduction:** The aim of this study was to evaluate the association between biomass formation and the clinical characteristics and prognosis of *Staphylococcus aureus* infective endocarditis (IE).

**Methods:** We prospectively studied 209 *S. aureus* strains causing IE. Biomass formation was examined using the crystal violet assay and quantified spectrophotometrically. The average (SD) optical density of the biomass was compared for each clinical, microbiological (methicillin-resistance, vancomycin MIC ≥ 1.5 µg/ml) and molecular (clonal complex, agr type and agr dysfunction) variable according to their presence or absence. The primary clinical endpoints studied were in-hospital death, severe sepsis, persistent bacteraemia, symptomatic peripheral embolisms and prosthetic valve IE.

**Results:** Mean age was 66.1 years, 61.5% of patients were male and the median age-adjusted Charlson comorbidity index was 5 points (IQR 3–8). In-hospital mortality was 37.3%. Strains belonging to CC5 and CC22 had optical biomass densities [mean (SD) 1.573 (1.14) vs 0.942 (0.98) \(p < 0.001\) and 1.720 (0.94) vs 1.028 (1.04) \(p < 0.001\), respectively]. Strains belonging to CC5 and CC22 had significantly higher optical biomass densities [1.369 (1.18) vs 0.920 (0.93) \(p = 0.008\)]. No statistically significant differences were found in the clinical endpoints studied.

**Conclusions:** High biomass production was associated with CC5 and CC22 but not with higher hospital mortality, septic complications, type of endocarditis, methicillin-resistance, elevated vancomycin MIC or agr dysfunction.

© 2019 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

**Asociación entre la formación de biomasa y el pronóstico de la endocarditis infecciosa causada por *Staphylococcus aureus***

**Resumen**

**Introducción:** La bacteriemia por *Staphylococcus aureus* es un problema de salud importante asociado a una elevada mortalidad. El objetivo de este estudio fue evaluar la asociación entre la capacidad de formación de biomasa y las características clínicas y el pronóstico de la endocarditis infecciosa (EI) por *Staphylococcus aureus*.

**Métodos:** Se estudiaron de forma prospectiva 209 cepas de *S. aureus* causantes de episodios de EI. La formación de biomasa se estudió mediante la técnica de cristal violeta y se cuantificó por espectrometría. La media (DE) de la densidad óptica de la biomasa se comparó para cada variable clínica, microbiológica (resistencia a la meticilina, CMI de vancomicina ≥ 1.5 µg/ml) y molecular (complejo clonal, tipo y
Introduction

Infective endocarditis (IE) is an uncommon and severe disease with in-hospital mortality around 20%, being greater than 30% in infections due to Staphylococcus aureus. The poor prognosis of S. aureus bacteremia is conditioned by factors associated with the host, the management of infection, and the intrinsic characteristics of the bacteria. Among the latter, there is a great need to determine whether factors other than antimicrobial resistance that are related to the prognosis can assist with decision making. In this sense, the production of biofilms is considered a variable that is associated with a worse prognosis although scientific evidence is scarce.

Recently, our group published a prospective study of 213 consecutive episodes of S. aureus IE with the aim of evaluating the impact of the phenotype and genotype on the clinical characteristics and prognoses of these patients. However, despite a recent study of 485 episodes of S. aureus bacteremia from different sources of infection found no relationship between biofilm production and a worse prognosis (30-day related mortality, infective endocarditis (IE), persistent bacteremia or recurrent bacteremia), we aimed to analyze the relationship between the biomass formation capacity and the clinical characteristics and prognosis of 209 consecutive episodes of S. aureus IE.

Methods

A detailed description of the study design can be found elsewhere. Briefly, a multicenter, longitudinal, prospective, observational study was performed in 15 hospitals with broad experience in IE. Between June 2013 and March 2016, consecutive adult patients (≥18 years) with a definite diagnosis of S. aureus IE were enrolled in the study.

Clinical, microbiological and prognostic variables were collected. The primary outcome was in-hospital death. Other clinical variables were healthcare-associated acquisition, previous use of antibiotics, severe sepsis/septic shock, persistent bacteremia 3 days after starting antimicrobial therapy, persistent bacteremia 5 days after starting antimicrobial therapy, symptomatic peripheral embolism (any), symptomatic ostearthicular involvement, native valve only IE, prosthetic valve IE, intracardiac device IE, surgery indicated and performed or indicated but not performed, and a composite end-point including persistent bacteremia 3 or 5 days after starting antimicrobial therapy plus symptomatic peripheral embolism (any).

In-hospital death was defined as all-cause death during the hospital stay. For this study, persistent bacteremia was registered as a categorical variable (demonstration of positive blood cultures ≥3 and ≥5 days after initiation of active antimicrobial therapy).

Disfunction of agr) according to its presence or absence. The criterion principal of valorization was the mortality hospitalaria. Otras variables clínicas evaluadas fueron: sepsemcia grave, bacteriemia persistente, embolías periódicas sintomáticas y se sobre válvula protésica.

Resultados: La edad media (DE) fue de 66,1 (16,2) años, el 61,5% eran varones y la mediana del índice de comorbilidad de Charlson ajustado a la edad fue de 5 puntos (RIC 3-8). La mortalidad hospitalaria fue del 37,3%. Las cepas pertenecientes a CC5 y CC22 presentaron densidades ópticas de biomasa significativamente más elevadas (media [DE] 1,573 [1,14] frente a 0,942 [0,981]; p = 0,001, respectivamente). Las cepas pertenecientes a los grupos agr1 mostraron mayores densidades ópticas de biomasa (1,369 [1,18] frente a 0,920 [0,93]; p = 0,008). No se observaron diferencias estadísticamente significativas en las variables clínicas estudiadas.

Conclusions: The production elevated of biomass was associated to determinated linajes clones (CC5 and CC22), but it was not associated to a mayor mortality hospitalaria, complications sépticas, type of endocarditis, resistencia a the meticilina, CMV of vancomicina elevated or disfunction of agr.

© 2019 Elsevier España, S.L.U. y Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Todos los derechos reservados.
could not be determined. Thus, we used 209 strains in the present study.

In the subgroups of patients analyzed, 113 (53.1%) infections were healthcare-associated, 143 (68.4%) affected native valves only, 39 (18.7) prosthetic valves, and 27 (12.9%) intracardiac devices. In 41 (19.6%) the infection was caused by a methicillin-resistant strain. Severe sepsis/septic shock was present in 95 (45.4%). After starting active treatment, persistent bacteremia at day 3 was demonstrated in 60 (28.7%) and at day 5 in 36 (17.2%). Symptomatic peripheral embolism was present in 103 (49.3%) and symptomatic osteoarticular metastasis in 25 (12.0%). Surgery was indicated in 133 (63.6%) but performed only in 79 (37.8%). In-hospital mortality was 37.3%.

Table 1 compares the mean (SD) optical densities of biomass for the 209 S. aureus strains included in the study according to the presence or absence of clinical, microbiological and molecular variables in 209 strains of S. aureus causing definite infective endocarditis.

<table>
<thead>
<tr>
<th>Variable</th>
<th>N (%)</th>
<th>Presence [mean (SD) of OD biomass]</th>
<th>Absence [mean (SD) of OD biomass]</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthcare-associated IE acquisition</td>
<td>111 (53.1)</td>
<td>1.074 (1.06)</td>
<td>1.089 (1.04)</td>
<td>0.918</td>
</tr>
<tr>
<td>Previous use of antibiotics (1 month)</td>
<td>49 (23.4)</td>
<td>1.004 (1.06)</td>
<td>1.105 (1.05)</td>
<td>0.362</td>
</tr>
<tr>
<td>Severe sepsis/septic shock</td>
<td>95 (45.4)</td>
<td>0.999 (1.02)</td>
<td>1.180 (1.08)</td>
<td>0.250</td>
</tr>
<tr>
<td>Persistent bacteremia at day 3</td>
<td>60 (28.7)</td>
<td>1.167 (1.15)</td>
<td>1.046 (1.01)</td>
<td>0.966</td>
</tr>
<tr>
<td>Persistent bacteremia at day 5</td>
<td>36 (17.2)</td>
<td>1.071 (1.07)</td>
<td>1.083 (1.05)</td>
<td>0.716</td>
</tr>
<tr>
<td>Symptomatic peripheral embolism</td>
<td>103 (49.3)</td>
<td>1.119 (1.07)</td>
<td>1.044 (1.02)</td>
<td>0.686</td>
</tr>
<tr>
<td>Osteoarticular metastasis</td>
<td>25 (12.0)</td>
<td>1.389 (1.32)</td>
<td>1.039 (1.00)</td>
<td>0.440</td>
</tr>
<tr>
<td>Native valve endocarditis only</td>
<td>143 (68.4)</td>
<td>1.555 (1.10)</td>
<td>0.930 (0.91)</td>
<td>0.444</td>
</tr>
<tr>
<td>Prosthetic valve endocarditis</td>
<td>39 (18.7)</td>
<td>0.982 (0.99)</td>
<td>1.104 (1.06)</td>
<td>0.406</td>
</tr>
<tr>
<td>Intracardiac device IE</td>
<td>27 (12.9)</td>
<td>0.831 (0.78)</td>
<td>1.118 (1.08)</td>
<td>0.098</td>
</tr>
<tr>
<td>Complications at day 3</td>
<td>127 (60.8)</td>
<td>1.070 (1.04)</td>
<td>1.054 (1.06)</td>
<td>0.848</td>
</tr>
<tr>
<td>Complications at day 5</td>
<td>117 (56.0)</td>
<td>1.102 (1.05)</td>
<td>1.054 (1.05)</td>
<td>0.657</td>
</tr>
<tr>
<td>Surgery indicated and performed</td>
<td>79 (37.8)</td>
<td>1.052 (0.91)</td>
<td>1.217 (0.91)</td>
<td>0.332</td>
</tr>
<tr>
<td>Surgery indicated but not performed</td>
<td>54 (25.8)</td>
<td>0.932 (1.02)</td>
<td>1.133 (1.05)</td>
<td>0.220</td>
</tr>
<tr>
<td>In-hospital mortality</td>
<td>78 (37.3)</td>
<td>1.244 (1.20)</td>
<td>0.984 (0.93)</td>
<td>0.425</td>
</tr>
</tbody>
</table>

Table 1: Comparison of the mean (SD) optical density of biomass according to the presence or absence of clinical, microbiological and molecular variables in 209 strains of S. aureus causing definite infective endocarditis.

Data are expressed as the mean (standard deviation). IE: infective endocarditis.

1 Composite end-point including persistent bacteremia 3 days after starting antimicrobial therapy plus symptomatic peripheral embolism (any).

2 Composite end-point including persistent bacteremia 5 days after starting antimicrobial therapy plus symptomatic peripheral embolism (any).

Discussion

In this study, high biomass production was not associated with higher crude in-hospital mortality, septic complications, type of endocarditis, healthcare-associated infections or previous use of antibiotics. Moreover, it was also not associated with methicillin resistance, elevated vancomycin MICs, or agr dysfunction. However, strains belonging to the clonal complexes CC5 and CC22 showed high biomass production, which was in contrast to the strains belonging to CC8, CC15 and CC45, which had significantly lower optical densities [0.328 (0.25) vs 1.174 (1.07), p < 0.001; 0.575 (0.84) vs 1.132 (1.05), p = 0.002; and 0.322 (0.14) vs 1.152 (1.07), p < 0.001, respectively]. The strains belonging to the agrII group showed a biomass optical density that was significantly higher than that of the rest of the agr groups [1.369 (1.18) vs 0.920 (0.93), p = 0.008]. Finally, no differences were found in agr dysfunction, methicillin resistance or vancomycin MICs.

5. S. aureus bacteremia is not a homogeneous entity but instead is a sign of the spread of an infection that can originate in very diverse locations. Unlike the study of Guembe et al., which included bacteremia due to S. aureus of any origin and in which no subgroups...
were analyzed, our study included only *S. aureus* strains causing definite episodes of IE. However, our study confirms the hypothesis that a high biomass production capacity is not related to a worse prognosis.

In the present study, CC5 and CC22 were the clonal complexes related to higher biomass production. However, none of these complexes was associated with mortality or complications in the previous clinical study. These results are consistent with those of another study of clinically invasive isolates, in which CC5 proved to be a strong biofilm producer. Conversely, CC8 and CC15, which were clonal complexes that produced fewer biomass, were respectively associated with higher in-hospital mortality and higher early mortality (≤2 days). Finally, CC45, which was the other clonal complex that produced fewer biomass, was related to infections on prosthetic valves and intracardiac devices.

*S. aureus* infective endocarditis is an acute infection. This characteristic could justify the absence of a clinical influence of biomass production showed in this study. Whatever the reason, our results are consistent with those of a recent study conducted on 159 *S. aureus* strains causing invasive infections, in which the strains causing endocarditis did not show a greater capacity for biofilm formation nor the production of biofilm was associated to complicated bacteremia, severe sepsis, 28-day mortality or recurrence.

No study is exempt from limitations. First, although the crystal violet assay is the most widely used method to quantify biomass production, we did not evaluate the metabolic activity of biofilm by means of XTT assay. Moreover, features such as host blood flow, serum proteins and other components of the immune system are not accurately reflected in the in vitro model. Second, we only measured biomass production by the first isolate from each episode; therefore, we do not know whether biomass production would have occurred in the strains of persistent isolates. Third, the correlation between the phenotypic test for the detection of *agr* operon dysfunction and its expression is not always good, and therefore the most appropriate technique would be quantification of RNAIII expression (gene effector of the *agr* operon).

In conclusion, in this study high biomass production was associated with some clonal lineages (CC5 and CC22) but was not associated with higher hospital mortality, septic complications or other predisposing factors.

**Investigators**


**Funding**

This work was supported by Fondo de Investigación Sanitaria (FIS), Ministerio de Sanidad, Instituto de Salud Carlos III (PI12/01719, PI12/01205, PI15/02013 and PI15/02125), the Ministerio de Economía y Competitividad, Instituto de Salud Carlos III, co-financed by the European Development Regional Fund A Way to Achieve Europe ERDF, Spanish Network for Research in Infectious Diseases (REIPI RD16/0160003 and REIPI RD16/0160002), and CIBER of Epidemiología y Salud Pública (CIBERESP), group CB06/02/0009. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

**Conflict of interest**

All authors declare that they have no conflicts of interest.

**References**